Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.76 |
| ▸ | NPC1 | O15118 | 2/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.72 |
| ▸ | KCNQ3 | O43525 | 6/20 | 0.71 |
| ▸ | KCNQ2 | O43526 | 6/20 | 0.71 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | MDM4 | O15151 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.64 |
| ▸ | KCNE1 | P15382 | 4/20 | 0.63 |
| ▸ | KCNQ1 | P51787 | 4/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3313800 | 0.89 | RAB9A (0.75) | RAB9AALDH1A1NPC1KDM4ESMN1; SMN2 | |
| SCHEMBL1986996 | 0.87 | KCNQ3 (0.82) | RAB9AALDH1A1SMN1; SMN2KCNQ3KCNQ2 | |
| SCHEMBL13210581 | 0.86 | ALDH1A1 (1.00) | RAB9AALDH1A1NPC1KDM4ESMN1; SMN2 | |
| SCHEMBL30834320 | 0.86 | ALDH1A1 (1.00) | RAB9AALDH1A1NPC1KDM4ESMN1; SMN2 | |
| SCHEMBL5215207 | 0.86 | KCNQ3 (0.81) | RAB9AALDH1A1SMN1; SMN2KCNQ3KCNQ2 | |
| SCHEMBL790983 | 0.84 | CYP11B1 (0.71) | RAB9ANPC1KDM4ESMN1; SMN2KCNQ3 | |
| SCHEMBL2801974 | 0.84 | KCNQ3 (0.85) | RAB9AALDH1A1SMN1; SMN2KCNQ3KCNQ2 | |
| SCHEMBL8361559 | 0.84 | RAB9A (1.00) | RAB9AALDH1A1NPC1SMN1; SMN2KCNQ3 | |
| SCHEMBL5217004 | 0.83 | KCNQ3 (1.00) | RAB9AKDM4ESMN1; SMN2KCNQ3KCNQ2 | |
| SCHEMBL14516647 | 0.83 | RAB9A (0.72) | RAB9AALDH1A1SMN1; SMN2KCNQ3KCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010143803-A2 | NEW NICOTINAMIDE DERIVATIVES WITH ANTI-ANDROGEN EFFECTS, PROCESSES OF PREPARING, AND ANTIANDROGENS COMPRISING THE SAME | INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY (KR) | 2010-12-16 | — | — | WO | claimed |
| EP-3757102-A1 | 5-ETHYL-4-METHYL-PYRAZOLE-3-CARBOXAMIDE DERIVATIVE HAVING ACTIVITY AS AGONIST OF TAAR | F. Hoffmann-La Roche AG (CH) | 2020-12-30 | — | — | EP | disclosed |
| EP-3430010-B1 | 5-ETHYL-4-METHYL-PYRAZOLE-3-CARBOXAMIDE DERIVATIVE HAVING ACTIVITY AS AGONIST OF TAAR | HOFFMANN LA ROCHE (CH) | 2020-07-15 | — | — | EP | disclosed |
| WO-2017157873-A1 | 5-ETHYL-4-METHYL-PYRAZOLE-3-CARBOXAMIDE DERIVATIVE HAVING ACTIVITY AS AGONIST OF TAAR | F. HOFFMANN-LA ROCHE AG (CH) | 2017-09-21 | — | — | WO | disclosed |
| US-9006450-B2 | Compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-9006450-B2 | Compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| EP-2350311-B1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | MADRIGAL PHARMACEUTICALS INC (US) | 2013-12-25 | — | — | EP | disclosed |
| US-8324385-B2 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324385-B2 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324385-B2 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| EP-1028945-B9 | SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | AMGEN INC (US) | 2009-02-18 | — | — | EP | disclosed |
| EP-1028945-B1 | SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | AMGEN INC (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2004026305-A9 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONIST | LILLY CO ELI (US) | 2004-05-13 | — | — | WO | disclosed |
| US-6458813-B1 | 2-CYCLOHEXYLOXY-5-(2-CHLOROPHENYLCARBONYLAMINO)PYRIDINE, FOR EXAMPLE; TREATING INFLAMMATION, PAIN, DIABETES, CANCER | AMGEN INC. | 2002-10-01 | — | — | US | disclosed |
| US-20020035094-A1 | Substituted pyridine compounds and methods of use | AMGEN INC. | 2002-03-21 | — | — | US | disclosed |
| US-6333341-B1 | TUMOR NECROSIS FACTOR, ANTIINFLAMMATORY AGENTS AND ANALGESICS | AMGEN INC. | 2001-12-25 | — | — | US | disclosed |
| US-6184237-B1 | Substituted pyridine compounds and methods of use | AMGEN INC. | 2001-02-06 | — | — | US | disclosed |
| EP-1028945-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | Amgen Inc. (US) | 2000-08-23 | — | — | EP | disclosed |
| US-6022884-A | PROPHYLAXIS OR TREATMENT OF INFLAMMATION | AMGEN INC. (US) | 2000-02-08 | — | — | US | disclosed |
| WO-1999024404-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | AMGEN INC. (US) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035094-A1 | Substituted pyridine compounds and methods of use | IL1B, IL6, IL1A | RAB9A 2767/4885ALDH1A1 257/4885NPC1 2800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.